Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients

American Journal of Gastroenterology

Volumn 97, Issue 10, 2002, Pages 2603-2608

  Brown, Kurt A ^a,b   Back, Susan J ^a   Ruchelli, Eduardo D ^a   Markowitz, Jonathan ^a,b   Mascarenhas, Maria ^a,b   Verma, Ritu ^a,b   Piccoli, David A ^a,b   Baldassano, Robert N ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ACCURACY; ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; CROHN DISEASE; DISEASE MARKER; DISEASE SEVERITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; EVALUATION AND FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOTHERAPY; INFANT; INTESTINE BIOPSY; LAMINA PROPRIA; ORGAN CULTURE; PREDICTION; PRIORITY JOURNAL; SERUM; SUPERNATANT; TISSUE LEVEL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; ORGAN CULTURE TECHNIQUES;

EID: 0036792754     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)04388-5     Document Type: Article

References (33)

1. Seidman E. Etiopathogenesis of inflammatory bowel disease: A pediatric perspective. Inflamm Bowel Dis 1998;4:204-9.
2. Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992;102:514-9.
3. Hosokawa T, Kusugami K, Ina K, et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 1999;14:987-96.
4. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999;34:66-74.
5. Kusugami K, Fukatsu A, Tanimoto M, et al. Elevation of interleukin-6 in inflammatory bowel disease is macrophage-and epithelial cell-dependent. Dig Dis Sci 1995;40:949-59.
6. Louis E, Belaiche J, Van Kemseke C, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol 1997;9:939-44.
7. Mahida YR, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991;32:1531-4.
8. Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-9.
9. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993;94:174-81.
10. Van Kemseke C, Belaiche J, Louis E. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis 2000;15:206-10.
11. Radford-Smith G, Jewell DP. Cytokines and inflammatory bowel disease. Baillières Clin Gastroenterol 1996;10:151-64.
12. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988;167:332-44.
13. Uyttenhove C, Coulie PG, Van Snick J. T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med 1988;167:1417-27.
14. Takai Y, Wong GG, Clark SC, et al. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 1988;140:508-12.
15. Koj A, Dubin A. On the hormonal modulation of acute-phase plasma protein synthesis in perfused rat liver. Acta Biochim Pol 1974;21:159-67.
16. Mazlam MZ, Hodgson HJ. Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994;35:77-83.
17. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992;103:1587-95.
18. Reimund JM, Wittersheim C, Dumont S, et al. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J Clin Immunol 1996;16:144-50.
19. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992;37:818-26.
20. Desreumaux P, Brandt E, Gambiez L, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997;113:118-26.
21. Bross DA, Leichtner AM, Zurakowski D, et al. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J Pediatr Gastroenterol Nutr 1996;23:164-71.
22. Hyams JS, Fitzgerald JE, Treem WR, et al. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993;104:1285-92.
23. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: Mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996;10(suppl 2):81-90.
24. , Brown KA, Kriss JA, Moser CA, et al. Circulating rotavirus-specific antibody-secreting cells (ASCs) predict the presence of rotavirus-specific ASCs in the human small intestinal lamina propria. J Infect Dis 2000;182:1039-43.
25. Grottrup-Wolfers E, Moeller J, Karbach U, et al. Elevated cell-associated levels of interleukin 1 beta and interleukin 6 in inflamed mucosa of inflammatory bowel disease. Eur J Clin Invest 1996;26:115-22.
26. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001;120:13-20.
27. Castell JV, Geiger T, Gross V, et al. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 1988;177:357-61.
28. Suzuki Y, Saito H, Kasanuki J, et al. Significant increase of interleukin 6 production in blood mononuclear leukocytes obtained from patients with active inflammatory bowel disease. Life Sci 1990;47:2193-7.
29. Unanue ER. Antigen-presenting function of the macrophage. Annu Rev Immunol 1984;2:395-428.
30. Glasser AL, Boudeau J, Barnich N, et al. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001;69:5529-37.
31. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000;164:4878-82.
32. Heikenen JB, Werlin SL, Brown CW, Balint JP. Presenting symptoms and diagnostic lag in children with inflammatory bowel disease. Inflamm Bowel Dis 1999;5:158-60.
33. Reinisch W, Gasche C, Tillinger W, et al. Clinical relevance of serum interleukin-6 in Crohn's disease: Single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999;94:2156-64.